Babis Andreadis, MD, MS

Education
M.S.C.E., 2005 - Pharmacogenetics, University of Pennsylvania, Philadelphia, PA
Fellow, 2004 - Hematology/Oncology, Hospital of the University of Pennsylvania
Resident, 2001 - Internal Medicine, Columbia-Presbyterian Medical Center
MD, 1998 - Medicine, College of Physicians & Surgeons, Columbia University, New York
BA, 1993 - Cum Laude, Biochemistry, Oberlin College, Oberlin, OH
Honors and Awards
  • Bay Area Man of the Year, Leukemia & Lymphoma Society, 2015
  • Finalist for the 2013-2014 Distinction in Teaching Award, UCSF, 2014
  • Marc A. Shuman Mentoring Award, Division of Hematology/Oncology, UCSF, 2013
  • Hematology Teaching Award, Division of Hematology/Oncology, UCSF, 2012
  • The Endocrine Society Medical Student Achievement Award, Columbia University, 1998
  • Alpha Omega Alpha, A of New York, 1997
  • Grove memorial Scholarship, Columbia University, 1996
  • McGraw-Hill Publishers Award, Columbia University, 1995
  • Nicholplus Interschool Fellowship, Columbia University, 1994
  • Harry N. Holmes Prize of Excellence in Chemistry, Oberlin college, 1993
  • Phi Beta Kappa, Z of Ohio, 1992
  • Franklin F. Jewett Award, Oberlin College, 1991
Websites
Publications

  1. Wang VE, Blaser BW, Patel RK, Behbehani GK, Rao AA, Durbin-Johnson B, Jiang T, Logan AC, Settles M, Mannis GN, Olin R, Damon LE, Martin TG, Sayre PH, Gaensler KM, McMahon E, Flanders M, Weinberg V, Ye CJ, Carbone DP, Munster PN, Fragiadakis GK, McCormick F, Andreadis C. Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis. Blood cancer discovery 2021. PMID: 34514432


  2. Kambhampati S, Fakhri B, Ai WZ, Kaplan LD, Tuscano JM, Wieduwilt MJ, Sudhindra A, Cavallone E, Reiner J, Aoun C, Castillo M, Martinelli M, Ta T, Le D, Padilla M, Crawford E, Andreadis CB. Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial. Clinical lymphoma, myeloma & leukemia 2020. PMID: 33478921


  3. Kambhampati S, Hunter B, Varnavski A, Fakhri B, Kaplan L, Ai WZ, Pampaloni M, Huang CY, Martin T, Damon L, Andreadis CB. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. Clinical lymphoma, myeloma & leukemia 2020. PMID: 33288485


  4. Nawas MT, Sheng Y, Huang CY, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Olin RL. Serial comprehensive geriatric and quality of life assessments in adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation. Journal of geriatric oncology 2020. PMID: 33059999